A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysis

Xavier Bonafont(Hospital Universitari Germans Trias i Pujol), Sean Robbins(Amgen (Switzerland)), Bastian Dehmel(Amgen (Switzerland)), F. Carrera(PHV Dialysezentrum), D. Carter(Amgen (United States)), R. Brunkhorst(Klinikum Region Hannover), Michaël Iskedjian, A. Böck(Kantonsspital Aarau), Bart Molemans(Amgen (United States))

Clinical Kidney Journal

August 4, 2009

10.1093/ndtplus/sfp097

Cited by 21

Related Papers

Epidemiology of sepsis in Germany: results from a national prospective multicenter study

|Intensive Care Medicine|2007|623

Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study

|BMJ|2012|309

First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients

|Journal of the American Society of Nephrology|2002|274

Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: A prospective, randomized study

|Arthritis & Rheumatism|1998|261

Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic–uraemic syndrome: an analysis of the German STEC-HUS registry

|Nephrology Dialysis Transplantation|2012|239